Curis Inc. Unveils Exciting Findings at the 30th Annual SNO Meeting Curis, Inc. will present groundbreaking clinical and preclinical data on emavusertib at the upcoming 30th SNO Meeting in November 2025.

Curis Inc. Unveils Exciting Findings at the 30th Annual SNO Meeting #United_States #Lexington #Curis #emavusertib #SNO_Meeting